Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis

Tecno Sun

Status and phase: Withdrawn; Phase 2

Conditions: Inverse Psoriasis; Sebopsoriasis

Treatments: Device: Halotherapy; Device: Placebo

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01574872

AEROSAL1

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy of Aerosal® compared to placebo in the prognosis of inverse psoriasis or sebopsoriasis present for at least one year

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Inverse Psoriasis or Sebopsoriasis lasting from at one year
• At least 1% of total body surface area involvement Suspension for more than 3 months from start of the study of any systemic drugs for psoriasis, immunosuppressive treatments (cyclosporin, systemic steroids), psoralen plus ultraviolet A irradiation (PUVA) or ultraviolet B phototherapy (UVB)

Exclusion criteria

• Patients with acute bronchopulmonary disease, tuberculosis, severe hypertension, hyperthyroidism, cancer (chemotherapy), intoxication, heart failure
• Iodine allergy
• Women who are pregnant or planning to become pregnant during the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 2 patient groups, including a placebo group

Aerosal

Experimental group

Description:

This arm include all patients treated with Aerosal®

Treatment:

Device: Halotherapy

Placebo

Placebo Comparator group

Description:

This arm include all patients treated with placebo

Treatment:

Device: Placebo